"A PHASE 2, MULTICENTER, SINGLE-ARM STUDY OF MOXETUMOMAB PASUDOTOX IN PEDIATRIC SUBJECTS WITH RELAPSED OR REFRACTORY PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA (PALL) OR LYMPHOBLASTIC LYMPHOMA OF B-CELL ORIGIN."

Registry ID

CAT-8015-1036

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

MEDIMMUNE LLC

Start date

2015-03-10

Last update

2013-04-17

Conditions

• LYMPHOBLASTIC LEUKEMIA
• DIFFUSE LARGE B-CELL LYMPHOMA

Related clinical trials

• Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma
• AN OPEN-LABEL, MULTICENTER, PHASE 1 TRIAL TO EVALUATE THE SAFETY, PHARMAKONETICS, AND ANTI-TUMOUR ACTIVITY OF TLN-121 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-LYMPHOMA AGENTS, IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS
• A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY OF ZILOVERTAMAB VEDOTIN (MK-2140) IN COMBINATION WITH R-CHP VERSUS R-CHOP IN PARTICIPANTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (WAVELINE-010)
• A PROSPECTIVE, MULTICENTER, PHASE II TRIAL TO EVALUATE THE EFFICACY OF ZANUBRUTINIB AND TISLELIZUMAB AS WELL AS STANDARD OF CARE FOR THE TREATMENT OF PATIENTS WITH PROGRESSIVE LYMPHOMA POST ANTI-CD19 CAR-T CELL THERAPY (ZETA)
• A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF GOLCADOMIDE PLUS R-CHOP CHEMOTHERAPY VS PLACEBO PLUS R-CHOP CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED HIGH-RISK LARGE B-CELL LYMPHOMA
• FEASIBILITY TRIAL OF GLOFITAMAB IN A RESPONSE ADAPTED APPROACH INCORPORATING INTERIM FDG PET AND CTDNA TO OPTIMIZE PRIMARY THERAPY OF DLBCL (GRAIL)

View on source registry